SCNI News and Press, Scanner Technologies Corp From 04/10/24

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG PR Newswire JERUSALEM , April 10, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: ...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, through its contract development and manufacturing organization (“CDMO”) business unit, Sc...

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services PR Newswire JERUSALEM , April 8, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that Ayana Pharma Ltd...

New research has found genes that could help forecast how non-small cell lung cancer may respond to a treatment combination of low-dose radiation and immunotherapy. The researchers explained that these genes could help identify tumors that were more likely to be destroyed by immunotherapies. I...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, will be participating at this month...

Scinai leadership to attend BIO-Europe Spring 2024 PR Newswire Showcasing Company's cGMP biologics CDMO and innovative NanoAb pipeline JERUSALEM , March 12, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company fo...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced that it will be attending the MIXiii In...

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024 PR Newswire JERUSALEM , Feb. 29, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing inflammation and im...

Patients with melanoma may soon be able to access a new immunotherapy that was recently approved by the U.S. Food and Drug Administration (FDA). The cell-based treatment, which was developed by Iovance Therapeutics, will first be administered by physicians at the Siteman Cancer Center in Wash...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as head ...